Article
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
The Journal of infectious diseases - 1 Oct 1991
Johnson V A, Merrill D P, Videler J A, Chou T C, Byington R E, Eron J J, D'Aquila R T, Hirsch M S
Abstract excerpt
Optimal management of human immunodeficiency virus type 1 (HIV-1) infections may require combinations of anti-HIV-1 agents. Zidovudine (AZT, 3'-azido-3'-deoxythymidine), didanosine (ddI, 2',3'-dideoxyinosine), and recombinant interferon-alpha A (rIFN-alpha A) were evaluated in two-drug regimens against replication of AZT-resistant HIV-1 in vitro. AZT-sensitive and AZT-resistant isolate pairs derived from two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.